Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

LEUVEN, Belgium, November 6 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update for the nine months period ended 30 September 2008.

Patrik De Haes, CEO of ThromboGenics, commenting on today's announcement, said: "ThromboGenics' clinical development programs continue to progress as anticipated. We are now working hard to prepare for the Phase III clinical program for microplasmin in eye disease following a successful End of Phase II Meeting with the FDA. The recent positive results from our Phase II trials with microplasmin have given us further confidence that this product has the potential to make a real difference in the field of eye disease. We are also developing a good working relationship with our strategic partner Roche as the clinical development of our new anti-cancer antibody TB-403 continues to progress. With our solid financial situation, I believe that ThromboGenics will deliver further important corporate milestones over the next 12 to 18 months as we continue to work to build value for our shareholders."
Financial Update

- In the first nine months of 2008, ThromboGenics achieved

revenues of EUR 30.3 million, mainly from out-licensing activities.

Operating expenses were EUR 17.0 million during this nine month period,

the majority of which were due to R&D expenses related to an increasing

number of clinical development programs.

- As of 30 September 2008, ThromboGenics had EUR 60.9 million

in cash and cash equivalents. This compares to EUR 50.6 million on 30

September 2007 and EUR 40.1 million on 31 December 2007. ThromboGenics

believes that this level of funding will allow it to complete the Phase

III program for the initial indication for microplasmin in eye disease.

- In late July, ThromboG
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 OHAUS Corporation, ... and mechanical balances and scales, proudly announces its ... won Laboratory Equipment magazine’s 2014 “Readers' Choice” Award ... consecutive year the Explorer was voted the best ... Readers’ Choice Awards celebrates “excellence in product design ...
(Date:7/22/2014)... SHENZHEN, China , July 22, ... (BGI Tech), a subsidiary of BGI, the world,s ... of a new human whole exome sequencing service ... offered service includes in-depth bioinformatics analysis and SNP ... December 31, 2014. Complete Genomics, ...
(Date:7/22/2014)... Quorum Review IRB, the industry leader in central ... called Quick Step™ . The offering went live on ... industry’s need for seamless study start-up with a large volume ... planning 50 or more North American investigator sites, as well ... count of 80 or more. Qualifying studies may also enroll ...
(Date:7/22/2014)... Sunnyvale, CA (PRWEB) July 22, 2014 ... begin on September 9th, 2014 and will comprise of ... and Application’ classes. The TechTrainings is a series of ... professionals, designed to help them reach the next step ... SAS class is taught by Jennifer Kang, Senior ...
Breaking Biology Technology:OHAUS Explorer Voted “Best Balance” in Laboratory Equipment’s 2014 Readers’ Choice Awards 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 3Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3Clinovo TechTrainings: Next Session of SAS and CDISC Classes Start 9th September, 2014 2Clinovo TechTrainings: Next Session of SAS and CDISC Classes Start 9th September, 2014 3
... IRVINE, Calif., March 14 Masimo Corporation,(Nasdaq: MASI ), ... pulse oximetry, today announced that it is scheduled,to present at ... The Four Seasons Hotel in Las Vegas, NV on Wednesday, ... and CEO, and Mark P. de,Raad, Executive Vice President and ...
... FRANCISCO, Calif., March 14 ,Renovis, Inc. (Nasdaq: RNVS ... of drugs for major medical needs in the areas ... fourth quarter and year ended December 31, 2007., ... December 31, 2007 was,$1.3 million and $9.8 million, respectively, ...
... Quest Diagnostics,Incorporated (NYSE: DGX ), the ... announced that it is scheduled to speak,at the ... Conference on,Tuesday, March 18, 2008, at the Marriott ... scheduled to begin at,8:45 a.m. Eastern Time., ...
Cached Biology Technology:Masimo to Present at Citi Investment Research 5th Annual Small & Mid-Cap Conference 2Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 2Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 3Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 4Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 5Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 6Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 7Quest Diagnostics to Speak at Cowen and Company 28th Annual Health Care Conference 2
(Date:7/22/2014)... Freezing and thawing might not be good for the ... each fall as they prepare to survive Alaska,s winter ... and thawing outside than a steak does in your ... the spring in better shape than the steak," said ... lead author on a recent paper demonstrating that freeze ...
(Date:7/22/2014)... for Health Policy and Economics have linked tighter ... rates for schizophrenic individuals. , The study comes ... health actually save money, when other costs are ... an extra approval step before tests or treatments ... called prior authorization is intended to encourage ...
(Date:7/22/2014)... light with uncanny precision are key parts of ... manipulate light instead of electricity. But producing these ... with a precise beam of electrons, is often ... Princeton and Columbia universities have proposed a new ... grow these specialized materials, known as photonic crystals, ...
Breaking Biology News(10 mins):Alaska frogs reach record lows in extreme temperature survival 2Alaska frogs reach record lows in extreme temperature survival 3Are state Medicaid policies sentencing people with mental illnesses to prison? 2Technique simplifies the creation of high-tech crystals 2Technique simplifies the creation of high-tech crystals 3
... federal state of Saxony-Anhalt most often suffers from ... by Brandenburg. Hans Hauner of Munich Technical University ... the regional differences in prevalence in general medical ... edition of Deutsches rzteblatt International ( ...
... critical of its life. Having run the gauntlet of air and ... must also evade hungry fish patrolling the beaches in its bid ... cays the risks are high: as many as 30% perish as ... headlong dash through the waves cost the intrepid hatchlings? Curious to ...
... solution to a sticky scientific problem in basic fluid ... even rate, but instead forms what look like fingers ... rivulets "gravity fingers," and the explanation for their formation ... wateror any liquidmeets the soil (or other medium). Knowing ...
Cached Biology News:Cost of hatchling turtles' dash for freedom 2MIT researchers explain mystery of gravity fingers 2
HSV-2 gD (0191)...
...
...
RayBio Human Angiogenesis Antibody Array 2.1 (8 array membranes) with Accessory, detects 23 angiogenic factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: